MGD 010

Drug Profile

MGD 010

Alternative Names: Anti-CD32B-anti-CD79B-bispecific-monoclonal-antibody; CD32BxCD79B; MGD010

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD79 antigen modulators; Fc gamma receptor IIB modulators; IgG receptor modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 17 Jun 2017 Updated pharmacokinetics and immunogenicity data from a phase I trial in Autoimmune disorders presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 01 Feb 2017 Macrogenis completes a phase I trial in Healthy volunteers in USA (NCT02376036)
  • 13 Dec 2016 Interim immunogenicity data from a phase I trial in Autoimmune disorders (In volunteers) released by Macrogenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top